Assessment of safety and tolerability of Herceptin subcutaneous administration in patients with HER2-positive early breast cancer: results of an open-label, randomized, multicenter, phase IIIB study. (March 2017) - Talayeva, S.; Kaidarova, D.; Zhavrid, E.; Prokharau, A.; Antonenkova, N.; Shatkovskaya, O.; Manasheva, A.; Rutzhanova, Z.